Cargando…

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone

BACKGROUND: Inhaled corticosteroids (ICS) afford therapeutic benefits in some COPD patients, but their widespread use is cautioned due to an increased risk of developing pneumonia. Subclass variations exist, and the risk profile differs for individual ICS. Formulation particle size has been identifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, David B, Henley, William, Cançado, José Eduardo Delfini, Fabbri, Leonardo M, Kerstjens, Huib A M, Papi, Alberto, Roche, Nicolas, Şen, Elif, Singh, Dave, Vogelmeier, Claus F, Barille, Sara, Nudo, Elena, Carter, Victoria, Skinner, Derek, Vella, Rebecca, Georges, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858000/ https://www.ncbi.nlm.nih.gov/pubmed/35210765 http://dx.doi.org/10.2147/COPD.S342357

Ejemplares similares

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Publicado: (2022)

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
por: Voorham, Jaco, et al.
Publicado: (2020)

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016)

Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma
por: Ming, Simon Wan Yau, et al.
Publicado: (2019)

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022)

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018)

Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients
por: Price, David, et al.
Publicado: (2013)

Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
por: Dean, James, et al.
Publicado: (2020)

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
por: Skloot, Gwen S., et al.
Publicado: (2023)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

2-Bromobeclometasone dipropionate
por: Ketuly, Kamal Aziz, et al.
Publicado: (2009)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study
por: Bakakos, Petros, et al.
Publicado: (2022)

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study
por: Gessner, Christian, et al.
Publicado: (2022)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study
por: Martin, Richard J, et al.
Publicado: (2014)

9α-Bromo analog of beclometasone dipropionate monohydrate
por: Ketuly, Kamal Aziz, et al.
Publicado: (2009)

A Feature Selection Approach Based on Interclass and Intraclass Relative Contributions of Terms
por: Zhou, Hongfang, et al.
Publicado: (2016)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Validation of an HPLC Analytical Method for the Quantitative/Qualitative Determination of Fluticasone Propionate in Inhalation Particles on Several Matrices
por: Sá Couto, André R., et al.
Publicado: (2014)

Improving Recognition of Overlapping Activities with Less Interclass Variations in Smart Homes through Clustering-Based Classification
por: Sarwar, Muhammad Usman, et al.
Publicado: (2022)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

New Pharmacologic Perspectives in Pneumology: Beclomethasone-Formoterol Extrafine
por: Paggiaro, Pierluigi
Publicado: (2009)

The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study
por: Singh, Dave, et al.
Publicado: (2017)

High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
por: Corradi, Massimo, et al.
Publicado: (2016)

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
por: Singh, Dave, et al.
Publicado: (2017)

An Intelligence EEG Signal Recognition Method via Noise Insensitive TSK Fuzzy System Based on Interclass Competitive Learning
por: Ni, Tongguang, et al.
Publicado: (2020)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
por: Zheng, Jinping, et al.
Publicado: (2021)

Characterizations and morphology of sodium tungstate particles
por: Dkhilalli, F., et al.
Publicado: (2018)

Iatrogenic Cushing’s syndrome with inhaled fluticasone
por: Ledger, Thomas, et al.
Publicado: (2019)

Single-Particle Tracking with Scanning Non-Linear Microscopy
por: Travers, Théo, et al.
Publicado: (2020)

Anemia: winning elbow room in the field of hematology and hemotherapy
por: Cançado, Rodolfo Delfini
Publicado: (2012)

Sickle cell disease: looking back but towards the future
por: Cançado, Rodolfo Delfini
Publicado: (2012)

Iron deficiency anemia and its treatment - reply
por: Cançado, Rodolfo Delfini
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pcj3easi4mgbecs6a62ne65uhe